| Ms Lisa Wilkerson, | |
|
2809 Denny Ave, Pascagoula, MS 39581-5301 | |
| (228) 809-5000 | |
| Not Available |
| Full Name | Ms Lisa Wilkerson |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 32 Years |
| Location | 2809 Denny Ave, Pascagoula, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366579047 | NPI | - | NPPES |
| LW00114294 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R815668 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Singing River Health System | Pascagoula, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jackson County Anesthesia | 9931292729 | 40 |
| Singing River Health System | 3870405194 | 156 |
News Archive
Using as ammunition a Florida judge's ruling this week that the federal healthcare law is unconstitutional, state officials are wasting no time stepping away from the controversial overhaul. Their latest move: rejecting a $1 million federal grant awarded to the Agency for Health Care Administration to plan a system required by the law where consumers can comparison shop for health plans.
IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.
Patients without time for a facelift or intimidated by surgery now have more minimally invasive options that produce effective results.
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
› Verified 1 days ago
| Entity Name | Singing River Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083893937 PECOS PAC ID: 3870405194 Enrollment ID: O20031104000435 |
News Archive
Using as ammunition a Florida judge's ruling this week that the federal healthcare law is unconstitutional, state officials are wasting no time stepping away from the controversial overhaul. Their latest move: rejecting a $1 million federal grant awarded to the Agency for Health Care Administration to plan a system required by the law where consumers can comparison shop for health plans.
IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.
Patients without time for a facelift or intimidated by surgery now have more minimally invasive options that produce effective results.
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
› Verified 1 days ago
| Entity Name | Jackson County Anesthesia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922159219 PECOS PAC ID: 9931292729 Enrollment ID: O20070913000898 |
News Archive
Using as ammunition a Florida judge's ruling this week that the federal healthcare law is unconstitutional, state officials are wasting no time stepping away from the controversial overhaul. Their latest move: rejecting a $1 million federal grant awarded to the Agency for Health Care Administration to plan a system required by the law where consumers can comparison shop for health plans.
IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.
Patients without time for a facelift or intimidated by surgery now have more minimally invasive options that produce effective results.
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
› Verified 1 days ago
| Entity Name | Singing River Gulfport |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861010159 PECOS PAC ID: 5294154829 Enrollment ID: O20201001001497 |
News Archive
Using as ammunition a Florida judge's ruling this week that the federal healthcare law is unconstitutional, state officials are wasting no time stepping away from the controversial overhaul. Their latest move: rejecting a $1 million federal grant awarded to the Agency for Health Care Administration to plan a system required by the law where consumers can comparison shop for health plans.
IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.
Patients without time for a facelift or intimidated by surgery now have more minimally invasive options that produce effective results.
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
› Verified 1 days ago
| Entity Name | Singing River Health System |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1740918937 PECOS PAC ID: 3870405194 Enrollment ID: O20221202000423 |
News Archive
Using as ammunition a Florida judge's ruling this week that the federal healthcare law is unconstitutional, state officials are wasting no time stepping away from the controversial overhaul. Their latest move: rejecting a $1 million federal grant awarded to the Agency for Health Care Administration to plan a system required by the law where consumers can comparison shop for health plans.
IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.
Patients without time for a facelift or intimidated by surgery now have more minimally invasive options that produce effective results.
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
› Verified 1 days ago
| Entity Name | Singing River Gulfport |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1780312504 PECOS PAC ID: 5294154829 Enrollment ID: O20230106000462 |
News Archive
Using as ammunition a Florida judge's ruling this week that the federal healthcare law is unconstitutional, state officials are wasting no time stepping away from the controversial overhaul. Their latest move: rejecting a $1 million federal grant awarded to the Agency for Health Care Administration to plan a system required by the law where consumers can comparison shop for health plans.
IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.
Patients without time for a facelift or intimidated by surgery now have more minimally invasive options that produce effective results.
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lisa Wilkerson, 2101 Highway 90, Gautier, MS 39553-5340 Ph: () - | Ms Lisa Wilkerson, 2809 Denny Ave, Pascagoula, MS 39581-5301 Ph: (228) 809-5000 |
News Archive
Using as ammunition a Florida judge's ruling this week that the federal healthcare law is unconstitutional, state officials are wasting no time stepping away from the controversial overhaul. Their latest move: rejecting a $1 million federal grant awarded to the Agency for Health Care Administration to plan a system required by the law where consumers can comparison shop for health plans.
IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.
Patients without time for a facelift or intimidated by surgery now have more minimally invasive options that produce effective results.
Genzyme, a Sanofi company, today announced that it has begun shipping Fabrazyme (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.
› Verified 1 days ago
Amanda Graham Dobbins, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-806-4525 | |
Mr. Laird Miller, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5000 | |
Andrew J Zielinski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5540 Fax: 228-809-1153 | |
Mr. Christopher Arlen Jones, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5531 Fax: 228-809-1153 | |
Jonathan White, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5000 | |
Mrs. Christine Cooper Bowman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5000 | |
Robert Shotlander, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5000 |